To address this knowledge gap, we designed a study to evaluate the cardiac safety of reduced cardiotoxicity surveillance in patients with HER2-positive breast cancer treated with a non-anthracycline chemotherapy regimen. The gene discussed is ERBB2; the disease is breast carcinoma.